Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vantictumab + nab-paclitaxel + gemcitabine
- Development stage
- Discontinued
- Lead developer
- Mereo BioPharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This combination comprises **vantictumab** (a fully human monoclonal antibody and Wnt signaling pathway inhibitor that targets the Frizzled family receptors FZD1, FZD2, FZD5, FZD7, and FZD8), **nab-paclitaxel** (an albumin-bound formulation of paclitaxel), and **gemcitabine** (a nucleoside analog used as chemotherapy)[3][4]. It has been investigated in phase 1b studies for the treatment of untreated metastatic pancreatic adenocarcinoma, aiming to augment cytotoxic chemotherapy by also targeting cancer stem cell pathways (through Wnt inhibition)[1][3][4]. Early clinical results showed partial responses and disease stabilization in some patients, but development was halted due to bone-related adverse events linked to vantictumab[3][4]. Vantictumab was developed by OncoMed Pharmaceuticals and the combination was tested in studies sponsored by OncoMed Pharmaceuticals and later, Mereo BioPharma[4][5].
- Other names
- vantictumab + nab-paclitaxel + gemcitabine
02
Targets
DNA polymerase familyFZD1 (Frizzled Receptor 1)FZD2 (Frizzled Receptor 2)FZD5 (Frizzled receptor 5)FZD7 (Frizzled class receptor 7)FZD8 (Frizzled Receptor 8)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vantictumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vantictumab + nab-paclitaxel + gemcitabine.